INTRODUCTION
The median survival time for patients for patients with the more malignant types of gliomas such as glioblastoma multiforme (GBM) is still a dismal 15 months despite multimodality therapy, including temozolomide (TMZ). [58] The prognosis is even worse for patients with brain metastasis from cancers such as melanoma, whose median survival time remains at 5 months. [50] Metastatic tumors are among the most common brain tumors, and in the United States there are an estimated 150,000 cases per year. Disease metastatic to the central nervous system (CNS) accounts for 20% of cancer deaths annually, a rate that can be traced to an increase in the median survival time of patients with cancer because of modern therapies, increased availability of advanced imaging techniques for early detection, and vigilant surveillance protocols for monitoring recurrence. Additionally, most systemic treatments (i.e., chemotherapeutic agents, which may penetrate the brain poorly) can transiently weaken the blood-brain barrier (BBB) and allow systemic disease to be seeded in the CNS, leaving the brain a safe haven for tumor growth. [43] Most of these patients with brain metastases are excluded from clinical trials owing to their poor prognosis. We are seeing an increased incidence of brain metastasis secondary to the increasing longevity of these patients. [4] There is clearly an unmet clinical need to develop therapeutic strategies that exert efficacy against CNS malignancies. Only now are pharmaceutical companies coming to the realization that there is a great untapped market for these agents, but few developmental chemists and translational researchers have considered CNS activity when developing drugs.
The signal transducer and activator of transcription 3 (STAT3) pathway is a potent regulator of tumorigenesis, tumor-mediated immune suppression, and metastasis to the brain. A variety of growth factors and cytokines activate STAT3 by phosphorylating the tyrosine residue in the STAT3 transactivation domain. Phosphorylated STAT3 (p-STAT3) then translocates into the nucleus and induces the expression of a wide variety of target genes involved in tumorigenesis. STAT3 is overexpressed almost ubiquitously in malignancies, including gliomas, [1] and propagates tumorigenesis by preventing apoptosis and enhancing proliferation, angiogenesis, invasiveness, and metastasis. [21, 66] The STAT3 pathway becomes constitutively active in diverse tumor-infiltrating immune cells, markedly impairing their antitumor effector responses [67] and enhancing the functional activity of immunosuppressive regulatory T cells (Tregs). [29] Glioma cancer stem cells (gCSCs) are also dependent on the STAT3 pathway, [56] including for their immunosuppressive properties. [59, 61] Targeting a molecular hub of both tumormediated immune suppression and tumorigenesis is a highly novel therapeutic strategy.
To target this pathway, several novel inhibitors of the STAT3 pathway have been designed and synthesized that show marked activity against intracerebral tumors in vivo both by directly interfering with tumorigenicity and by reversing tumor-mediated immune suppression. Our data demonstrate the highly promising potential application of one of these, WP1066, which we have been extensively developing. We hypothesize that by targeting multifactorial signaling mediated by the STAT3 pathway and reversing immunosuppression, we can improve survival in patients with gliomas and brain metastasis -a typically underserved patient population that continues to have a dismal survival prospect.
BACKGROUND
STAT3 is a key transcription factor that drives the fundamental components of malignancy and metastasis including those in gliomas. In many tumors, STAT3 is constitutively active including the unphosphorylated form which is also capable of inducing oncoproteins. [65] GBM tumors and glioma cell lines have been shown to have high levels of both in comparison to normal brain tissue. [46] We have shown that STAT3 is overexpressed in most gliomas and is a negative prognostic marker for survival in patients who have malignant glioma. [1] STAT3 has also been shown to be a master regulator for mesenchymal transformation in brain tumors. [6] The STAT3 pathway is also either likely to be or is actually overexpressed in other types of more benign CNS tumors, such as choroid plexus papilloma, [39] ependymoma, [7] and meningioma. [25] STAT3 has also been shown to be crucial to tumorigenesis and a mediator of poor prognosis in a wide variety of other malignancies, such as gastric and colon cancers, [14] renal cancer, [20] ovarian cancer, [38] squamous cell cancer, [37, 55] hepatocellular carcinoma, [62] and anaplastic large cell lymphoma. [27] A study by Xie et al. [64] confirmed the importance of STAT3 in melanoma metastasis by showing that only highly metastatic melanoma cell lines, but not poorly metastatic ones, have elevated levels of activated STAT3 (p-STAT3). Furthermore, blockade of activated STAT3 prevents the invasiveness of melanoma cells, inhibits tumor growth, and prevents metastasis, suggesting that STAT3 activation is the crucial event in melanoma metastasis. Subsequent tissue microarray studies of brain metastasis in human melanoma patients have demonstrated higher levels of expression of activated STAT3 in melanoma brain metastasis specimens compared with those from parenchymal tumors. [63] Thus, this ubiquitous pathway is upregulated in almost all malignancies studied thus far, especially within CNS tumors.
STAT3 has also been implicated as a key regulator of immunosuppression in patients with cancer, and is therefore considered a potential target for immunotherapy. [67] The p-STAT3 pathway is induced in the immune cells within the tumor microenvironment, [32] which downregulates their antitumor immune responses. Specifically, p-STAT3 has been shown to suppress macrophage activation and to limit their inflammatory responses, [44] reduce natural killer (NK) cell and neutrophil cellular cytotoxicity, and reduce the expression of major histocompatibility complex (MHC) II, CD80, CD86, and interleukin (IL)-12 in dendritic cells, rendering them unable to stimulate T cells and to generate effective antitumor immunity. [32] STAT3 activation enhances the suppressive activities of human Tregs by upregulating FoxP3 expression. [68] Tumor-associated macrophages (MΦ)/microglia have been shown to become polarized via the STAT3 pathway toward immunosuppressive and tumor supportive phenotypes (M2) that then contribute to angiogenesis and tumor invasion. [35] Cumulatively, these data indicate that STAT3 is a key pathway that prevents the immune system from recognizing and eliminating malignancy from our bodies.
Finally, the p-STAT3 pathway is a fundamental hub for the control of gCSCs, [56] which are undifferentiated cells with the capacity for self-renewal and a high proliferative potential. The gCSCs confer the resistance to chemotherapy and radiation that is observed in cancer patients. [3, 40] Many investigators believe that without targeting this subpopulation of cells therapeutically, tumors will continue to persist and recur. Implantation of gCSCs in mice recapitulates the key characteristics of human malignancies. [52] The gCSCs frequently have overexpression of p-STAT3, which results in proliferation and tumorigenic potential. [10] We have also shown that the gCSCs are highly immunosuppressive, [59] and when we block STAT3 in the gCSCs with WP1066, there is nearly complete reversal of tumor-mediated immune suppression. [59, 61] The use of p-STAT3 inhibitors to overcome tumor-mediated immune suppression may result in the ability of the immune system to recognize and eradicate the tumor, which the tumor typically prevents it from doing. Cumulatively, these data indicate that targeting the STAT3 pathway is a multipronged approach that is truly unique.
RESULTS AND DISCUSSION
WP1066 is an analogue of caffeic acid that is a very potent and specific inhibitor of p-STAT3. [36, 45] It has been shown to induce apoptosis in gliomas by downregulating the antiapopototic proteins Mcl-1, Bcl-X L and c-Myc, while activating Bax. [24] In other types of solid malignancy, WP1066 has been shown to inhibit vascular endothelial growth factor (VEGF) production by the tumor and associated in vivo angiogenesis, [19, 33] indicating that inhibition of STAT3 results in a multiplicity of antitumor mechanisms. When WP1066 was administered to mice orally, toxicity was minimal. Detailed histological examination of the spleen, kidney, lung, heart, and bone marrow demonstrated no significant abnormalities in mice given the 40-mg/kg dose by oral gavage. Because WP1066 is a potent immune activator, nonspecific immune reactivity in the CNS remains a consideration; however, Luxol fast blue staining of the CNS failed to demonstrate any evidence of CNS autoimmunity. Thus, preliminary toxicology has demonstrated that WP1066 has an extremely desirable profile. [29] Bioavailability studies after oral administration yielded mean peak plasma concentrations greater than 2 µM. Furthermore, kinetic data indicate that WP1066 has a marked ability to achieve excellent CNS penetration, exceeding 30 µM concentrations within the CNS of mice with an intact BBB, and the brain drug levels were long lasting (weeks). These doses markedly exceed the direct antitumor effects on cancer stem cells and tumor-mediated immune suppression.
Other studies have demonstrated statistically significant suppression of tumor growth in mice with head and neck carcinoma, [34] pancreatic cancer, [2, 15] bladder cancer, [8] glioma, [24] B-cell non-Hodgkin's lymphoma and myeloma, [28] and chronic myelogenous leukemia, [48] when given WP1066. Treatment of established tumors in vivo with WP1066 has resulted in decreased tumor proliferation, tumor volume, and angiogenesis/vascular proliferation. [34] To determine whether treatment with WP1066 is efficacious against intracerebral tumors established in mice, the mice were treated with WP1066. Median survival durations and rates were markedly enhanced when WP1066 was administered, and 80% of WP1066-treated animals survived long term compared with 0% of control mice treated with the injection vehicle control (P = 0.0076). [29] Similar results have been seen in other animal model systems of intracranial gliomas. [31] Specifically, using the RCAS/Ntv-a system, mice were engineered to coexpress platelet-derived growth factor receptor (PDGF)-B + B-cell lymphoma (Bcl)-2 under the control of the glioneuronal-specific Nestin promoter. In mice expressing both PDGF-B + Bcl-2 that were treated with WP1066, there was a 55.5% increase in median survival time (P < 0.01), with an associated inhibition of intratumoral p-STAT3 and macrophages. These data demonstrate the compelling efficacy of WP1066 against established tumors in the CNS in multiple murine models.
In addition to the ability of WP1066 to enhance immune-mediated antitumor immune responses, [29] it also markedly inhibited Tregs in vivo. [30] We have also shown that WP1066 can upregulate costimulatory molecules (CD80, CD86) on ex vivo human microglia isolated from glioma patients, induce proinflammatory cytokine secretion essential for T effector responses, and induce impaired T cells to become activated and proliferate, indicating that STAT3 blockade is a potent approach for modulating immunosuppression. [22] Other investigators have shown that by ablating STAT3 in the hematopoietic cells in mice, there was marked enhancement of function within T cells, NK cells, and dendritic cells in tumor-bearing mice. This ablation of STAT3 in only the hematopoietic cells resulted in marked antitumor effects in vivo, indicating that STAT3 expression within the immune cells is what restrains the antitumor immune eradication. [32] This indicates that WP1066 could also be developed as an immunotherapeutic for malignancies. Finally, we have shown that WP1066 can target glioma cancer stem cells that are responsible for therapeutic resistance. [59, 61] There are several other STAT3 inhibitory compounds that have therapeutic potential for introduction into clinical trials for patients with CNS malignancies [ Table 1 ]. JSI-124 (cucurbitacin I) [54] has demonstrated prolonged survival in murine model systems with intracerebral tumors [13] and also has a favorable toxicity profile. [42] JSI-124 has in vitro activity against lymphoma [57] and cervical cancer [9] and in vivo growth inhibition of human breast carcinoma and syngeneic murine melanoma, but not in carcinomas that lack constitutive expression of p-STAT3. [5] Immunomodulatory properties of JSI-124 include the ability to overcome the dendritic cell differentiation block induced by tumors, resulting in the upregulation of MHC class II and costimulatory molecules and subsequent functional T-cell stimulation/activation. [41] In an in vivo sarcoma model in which JSI-124 had minimal direct tumor cytotoxicity, JSI-124 enhanced dendritic cell vaccination, resulting in marked tumor suppression that persisted for more than 4 weeks. [42] Furthermore, JSI-124 in vivo promoted a Th1 (cytotoxic effector) phenotype and enhanced the levels of glioma-infiltrating immune cells. [13] Immune-competent mice with intracerebral tumors treated with JSI-124 had prolonged survival, but this efficacy was not observed in an immuneincompetent background, indicating that the immune system played a role in the in vivo effect of JSI-124 in a manner similar to WP1066. Furthermore, when JSI-124 was combined with adoptive transfer of type I cytotoxic T lymphocytes, survival was further enhanced compared with treatment with either modality alone. The authors concluded that the inhibition of STAT3 could reverse the immunosuppressive immune microenvironment and promote the efficacy of adoptive transfer therapy. [13] Finally, although described as an inhibitor of janus kinase 2 (Jak2; which is upstream of STAT3), AZD1480 also possesses serious clinical potential for the treatment of patients with CNS malignancies. AZD1480 has demonstrated significant growth inhibition on a wide variety of human solid tumor xenografts [16] and myeloproliferative neoplasms [23, 53] and is already in phase I clinical trials. Thus, there are several serious contenders that can block STAT3, which are likely to be introduced into clinical trials for patients with gliomas within the next few years.
CURRENT AND FUTURE DEVELOPMENTS
The potential for using p-STAT3 inhibitors in the treatment of a variety of cancers, including CNS metastasis, is evident. After successful completion of phase I testing, an interesting application of these compounds will be in combination with other immunotherapeutic strategies. For example, p-STAT3 inhibitors could be used in combination with dendritic cell vaccinations. Alternatively, in the treatment of high-grade malignant gliomas, we have previously shown that a peptide vaccine (PEP-3-KLH/CDX-110) directed to the splice junction of type III variant of the epidermal growth factor receptor (EGFRvIII) is effective in the treatment of intracerebral tumors in both murine models [18] and human patients who have newly diagnosed GBM. [49, 51] These trials were limited to GBM patients who underwent gross-total resections so that the immunosuppressive properties of the tumor were negated as much as possible. However, many GBM patients cannot have a surgical resection that places their disease in a microscopic residual infiltrative state, and therefore, agents that can counteract the immunosuppressive influence of a bulky tumor are essential. Within malignant glioma patients, there is a prominent Treg population in the systemic circulation [12] and marked infiltration within the tumors in the CNS. [17] These Tregs remain elevated even in patients receiving PEP-3-KLH. [49] Because the p-STAT3 agents inhibit Tregs, enhance cytotoxic responses, and reverse immune suppression, they have the potential to further enhance peptide-based vaccination strategies, such as with the PEP-3-KLH/CDX-110 vaccine, possibly including patients with bulky tumors who are unable to undergo surgical resection.
Emerging within the glioma literature is the concept that STAT3 may be upregulated during treatment failure. Specifically, treatment with imatinib (Gleevec ® ) resulted in the sustained activation of STAT3 in malignant cells. [11] Other investigators have suggested that anti-VEGF treatment can reduce the blood supply within gliomas, leading to a more hypoxic environment. [26] Moreover, we have recently demonstrated that hypoxia can induce the expression of p-STAT3. [60] Thus, it is possible that the failure of anti-VEGF strategies may be associated with upregulation of STAT3. If this is the case, then agents targeting the STAT3 pathway given in combination with anti-VEGF therapeutics may prevent or delay tumor recurrence and/or may be an appropriate salvage therapy. [47] In summary, STAT3 blockade agents have multiple mechanisms of activity, including direct tumor cytotoxic effects and the ability to overcome the negative modulatory effects of the local tumor microenvironment, allowing for immunological recognition and clearance of cancer cells. The targets of STAT3 blockade agents are not only the STAT3 in tumor cells, but also the STAT3 in immune cells, which use the p-STAT3 pathway to prevent antitumor immune reactivity. The preclinical data thus far available are sufficiently compelling to justify the consideration of human clinical trials to test these agents. The small molecule inhibitors of p-STAT3 can be used to treat a wide variety of cancers but, in particular, may have a meaningful impact on patients with primary and metastatic tumors of the CNS, a markedly underserved patient population.
